Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377574 | 0.84 | GRIK1 (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL5082998 | 0.84 | GRIK1 (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2130589 | 0.84 | GRIK1 (0.73) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Ornithine SCHEMBL7429185 | 0.83 | GRIK1 (0.47) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Phenylacetic Acid SCHEMBL16975021 | 0.83 | AKR1B1 (0.55) | GRIK1LTA4HGSRALPIPKM | |
| Phenylacetic Acid SCHEMBL1702338 | 0.83 | AKR1B1 (0.55) | GRIK1LTA4HGSRALPIPKM | |
| Homophenylalanine SCHEMBL14331297 | 0.83 | GSR (0.65) | GRIK1CPB2LTA4HGSRALPI | |
| Homophenylalanine SCHEMBL27675878 | 0.83 | GSR (0.65) | GRIK1CPB2LTA4HGSRALPI | |
| Hydrochloric Acid SCHEMBL7359673 | 0.82 | GRIK1 (0.71) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3390123 | 0.82 | GRIK1 (0.66) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250221954-A1 | METHODS TO TREAT, PREVENT, OR REDUCE HYPERAMMONEMIA | RUBIN DARREN ALEXANDER (US) | 2025-07-10 | — | — | US | claimed |
| US-20250221954-A1 | METHODS TO TREAT, PREVENT, OR REDUCE HYPERAMMONEMIA | RUBIN DARREN ALEXANDER (US) | 2025-07-10 | — | — | US | disclosed |
| EP-3686183-B1 | L-ORNITHINE PHENYL ACETATE AND METHODS OF MAKING THEREOF | OCERA THERAPEUTICS INC (US) | 2022-08-03 | — | — | EP | disclosed |
| US-10610506-B2 | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy | UCL BUSINESS LTD (GB) | 2020-04-07 | — | — | US | disclosed |
| US-20170189364-A1 | COMPOSITIONS COMPRISING ORNITHINE AND PHENYLACETATE OR PHENYLBUTYRATE FOR TREATING HEPATIC ENCEPHALOPATHY | VTESSE LLC | 2017-07-06 | — | — | US | disclosed |
| EP-2319581-B1 | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy | UCL BUSINESS PLC (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2153870-B1 | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy | UCL BUSINESS PLC (GB) | 2013-12-25 | — | — | EP | disclosed |
| US-8389576-B2 | Using ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy; isoleucine may also be administered; brain disorders effected by liver disorders | UCL BUSINESS PLC (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2319581-A1 | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy | UCL Business PLC (GB) | 2011-05-11 | — | — | EP | disclosed |
| EP-2153870-A1 | Compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy | UCL Business PLC (GB) | 2010-02-17 | — | — | EP | disclosed |
| US-20080119554-A1 | Compositions Comprising Ornithine And Phenylacetate Or Phenylbutyrate For Treating Hepatic Encephalopathy | VTESSE LLC | 2008-05-22 | — | — | US | disclosed |
| EP-1824563-A1 | COMPOSITIONS COMPRISING ORNITHINE AND PHENYLACETATE OR PHENYLBUTYRATE FOR TREATING HEPATIC ENCEPHALOPATHY | UCL Business PLC (GB) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006056794-A1 | COMPOSITIONS COMPRISING ORNITHINE AND PHENYLACETATE OR PHENYLBUTYRATE FOR TREATING HEPATIC ENCEPHALOPATHY | UCL BUSINESS PLC (GB) | 2006-06-01 | — | — | WO | disclosed |